Crown Bioscience, in partnership with leading third-party proteomics providers, offers next-generation ion mobility mass spectrometry (MS)-based proteomics services to global clients.
This will allow clients to assess the biological function of proteins for understanding signaling mechanisms within cells as well as specific biomarkers to diseases, and systematically assess quantitative differences in protein profiles of distinct samples for biomedical and clinical research.
No missing values, reduced batch effect, better data parallelism, and traceability
Increased sensitivity and wider dynamic range, improved detection depth:
Identify more proteins from same or lower amount of sample, significantly improved quantification especially for low abundant proteins
Lower amount of samples required
Suitable for large sample cohort studies
Proteomic biomarker discovery service
Customized bioinformatic analysis available for large cohort studies
Most diseases are manifested at the level of protein activity. Proteomics seeks to directly correlate the involvement of specific proteins, protein complexes and their modification status in disease states. The level of transcription of a gene gives only a rough estimate of its level of expression into a protein, and moreover, it cannot reflect the protein post transcription modifications which profoundly affect their activities.
Liquid chromatography (LC) coupled with mass spectrometry (MS) has become the gold standard in various omics fields. However, the proteome is highly complex with a wide dynamic range, and the coverage of proteomes in complex biological samples remains challenging due to the limited speed, sensitivity, and resolution of current mass spectrometers.
Liquid chromatography (LC) coupled with mass spectrometry has become the gold standard in various omics fields. When choosing MS-based proteomic services, there are several factors to consider: